EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases

Heng Zhang, Meng Yao Li, Wei Deng

Biochemical Pharmacology · 2026-10 · 252 · 118201

DOI: 10.1016/j.bcp.2026.118201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-10. Verfasst von Heng Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Metabolism and Related Chronic Diseases, …. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Naphthyridines, Cardiovascular Diseases, Metabolic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 223 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hubei Province Department of Science and Technology, National Postdoctoral Program for Innovative Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases (CVDs) remain a leading cause of global mortality, necessitating novel therapeutic strategies. Mineralocorticoid receptor (MR) overactivation drives pathological inflammation, fibrosis, and oxidative stress in cardiovascular and renal tissues. Traditional steroidal mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, are limited by adverse effects including hyperkalemia and endocrine disturbances. Finerenone, a novel nonsteroidal MRA, offers enhanced MR selectivity and an improved safety profile. This review provides a comprehensive overview of finerenone's pharmacology, preclinical evidence, and clinical applications. Finerenone exerts potent anti-inflammatory, anti-fibrotic, and antioxidant effects, conferring cardiorenal protection in diabetic kidney disease (DKD), heart failure with preserved ejection fraction (HFpEF), hypertension, myocardial infarction, atrial fibrillation, and left ventricular hypertrophy. Key clinical trials (FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF) demonstrate that finerenone reduces composite cardiovascular and renal outcomes with a lower risk of hyperkalemia compared to steroidal agents. Emerging evidence supports its expanding role in diabetic cardiomyopathy and heart failure with reduced ejection fraction. However, challenges remain, including the need for long-term safety data, personalized treatment strategies, and elucidation of non-genomic MR signaling mechanisms. This review concludes that finerenone represents a promising therapeutic advancement, and ongoing research will further optimize its clinical use to improve patient outcomes in cardiorenal diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsNaphthyridinesCardiovascular DiseasesMetabolic DiseasesHumansAnimals

Stichwörter der Autor:innen

Cardiovascular diseaseDiabetic kidney diseaseFinerenoneHeart failureHyperkalemiaMineralocorticoid receptor antagonists

Substanzen

finerenoneMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Metabolism and Related Chronic Diseases, Wuhan 430060, China.
  • Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Metabolism and Related Chronic Diseases, Wuhan 430060, China. Electronic address: vivideng1982@whu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Hubei Province Department of Science and Technology
  • National Postdoctoral Program for Innovative Talents
  • China Postdoctoral Science Foundation
  • Hubei Provincial Department of Education
  • National Key Laboratory Foundation of China

Zitieren

APA

Zhang, H., Li, M. Y., & Deng, W. (2026). Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases. Biochemical Pharmacology, 252, 118201. https://doi.org/10.1016/j.bcp.2026.118201

Vancouver

Zhang H, Li MY, Deng W. Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases. Biochemical Pharmacology. 2026;252:118201. doi:10.1016/j.bcp.2026.118201

BibTeX
@article{Zhang2026,
  author = {Zhang, Heng and Li, Meng Yao and Deng, Wei},
  title = {Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {252},
  pages = {118201},
  doi = {10.1016/j.bcp.2026.118201}
}
Kostenlos starten →